4A40.1 Drug-induced lupus erythematosus International Classification of Diseases for Mortality and Morbidity Statistics, 11th Revision, v2024-01 Drug-induced lupus erythematosus is a syndrome in which positive antinuclear antibodies are associated with symptoms, such as fever, malaise, arthritis, intense arthralgia/myalgia, serositis, and/or rash. The syndrome appears during therapy with certain medications (e.g., procainamide, hydralazine, phenytoin) and tumour necrosis factor inhibitors. It occurs predominantly in Caucasians, has less female predilection than SLE, rarely involves kidneys or brain, is rarely associated with anti-dsDNA, is commonly associated with antibodies to histones, and usually resolves over several weeks after discontinuation of the offending medication.
postcoordination Add Stem and/or Extension codes to form a cluster code which adds detail to the condition.
Has manifestation - multiple selections are allowed [select] MG30.30 Chronic secondary musculoskeletal pain from persistent inflammation Associated with - multiple selections are allowed [select] PL00 Drugs, medicaments or biological substances associated with injury or harm in therapeutic use PL01 Complementary or traditional medicines associated with injury or harm in therapeutic use – PL01.0 Complementary or traditional medicines associated with injury or harm in therapeutic use, Herbal Preparations or Formulas – PL01.1 Complementary or traditional medicines associated with injury or harm in therapeutic use, Dietary Supplements, Vitamins or Minerals – PL01.2 Complementary or traditional medicines associated with injury or harm in therapeutic use, Complementary or Traditional Medicines, not elsewhere classified – PL01.Y Other specified complementary or traditional medicines associated with injury or harm in therapeutic use – PL01.Z Complementary or traditional medicines associated with injury or harm in therapeutic use, unspecified PL0Z Substances associated with injury or harm in therapeutic use, unspecified PL13 Mode of injury or harm associated with exposure to a drug, medicament or biological substance PL13.0 Overdose of substance, as mode of injury or harm PL13.1 Underdosing, as mode of injury or harm PL13.2 Drug-related injury or harm in the context of correct administration or dosage, as mode of injury or harm PL13.3 Incorrect substance, as mode of injury or harm PL13.5 Incorrect administration of drug or medicament, as mode of injury PL13.6 Medication or substance that is known to be an allergen, as mode of injury or harm PL13.7 Medication or substance that is known to be contraindicated for the patient, as mode of injury or harm PL13.8 Expired or deteriorated medication or substance, as mode of injury or harm PL13.9 Drug or substance interactions, as mode of injury or harm PL13.A Inappropriate stoppage or discontinuation of drug, as mode of injury or harm PL13.Y Other specified mode of injury or harm associated with exposure to a drug, medicament or biological substance PL13.Z Mode of injury or harm associated with exposure to a drug, medicament or biological substance, unspecified – PL13.50 Incorrect route of drug or medicament, as mode of injury – PL13.51 Incorrect rate of drug or medicament, as mode of injury – PL13.52 Incorrect timing of drug or medicament, as mode of injury – PL13.53 Incorrect duration of drug or medicament, as mode of injury – PL13.5Y Other specified incorrect administration of drug or medicament, as mode of injury – PL13.5Z Incorrect administration of drug or medicament, as mode of injury, unspecified
synonyms Drug-induced lupus erythematosus drug-induced systemic lupus erythematosus
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com